X

Trial Profile

Phase III trial of ORL-101 in patients with Leukocyte Adhesion Deficiency Type II

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 24 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fucose (Primary)
Indications Congenital disorder of glycosylation type 2C
Focus Registrational; Therapeutic Use

Most Recent Events

23 Feb 2022 According to an Orpha Labs media release, the company initiating a rolling submission of the NDA in the United States.
23 Feb 2022 According to an Orpha Labs media release, the company is working with investigators to switch patients from a compassionate use study initiated last year to this Phase III study.
23 Feb 2022 Status changed from planning to recruiting, according to an Orpha Labs media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com